The FDA has recently released a public health advisory warning of a high incidence of patients experiencing marked behavioral changes, depressed mood, suicidal behavior and other neuropsychiatric synmptoms after taking the anti-smoking drug Chantix.  The FDA has requested that the manufacturer of the drug, Pfizer, apply stronger warnings to product labels and prescription information.  The FDA warning also indicates that Chantix can cause worsening of psychiatric symptoms in people who are currently being treated for them as well as recurrence of old psychiatric illness.

Wilson Kehoe & Winingham is currently representing several clients in cases in which persons suffered severe adverse health effects, including suicide, dramatic mood changes, and suicidal behavior.  If you or a loved one have experienced mood changes, depression, agitation, thoughts of suicide or actual suicidal behavior as a result of taking Chantix, please contact us at 1-800-525-8028 or fill out a brief case submission form. 

For more information regarding Chantix, please see the following:

From the New York Times

F.D.A. Investigates Quit-Smoking Drug http://www.nytimes.com/2007/11/21/business/21pfizer.html?_r=1&oref=slogin

From USA Today

FDA: Chantix may pose psychiatric risks http://www.usatoday.com/news/health/2008-02-01-220606507_x.htm

CBS TV station video report regarding Chantix http://cbs11tv.com/video/?id=21579@ktvt.dayport.com&cid=7

Video from CNBC

FDA Warns Against Pfizer's Chantix

The FDA says there is a likely association between Pfizer's Chantix and serious psychiatric behavior, reports CNBC's Mike Huckman

http://www.cnbc.com/id/15840232?video=633431083&play=1